AstraZeneca’s (AZN) “Buy” Rating Reiterated at Deutsche Bank

Share on StockTwits

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by analysts at Deutsche Bank in a research note issued on Tuesday, Digital Look reports. They currently have a GBX 6,800 ($88.85) target price on the biopharmaceutical company’s stock. Deutsche Bank’s price objective would indicate a potential upside of 5.43% from the stock’s previous close.

A number of other brokerages also recently weighed in on AZN. Liberum Capital reiterated a “hold” rating on shares of AstraZeneca in a report on Friday, March 29th. Jefferies Financial Group reiterated a “hold” rating on shares of AstraZeneca in a report on Thursday, March 14th. Goldman Sachs Group reiterated a “sell” rating on shares of AstraZeneca in a report on Monday, March 18th. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a report on Monday, March 11th. Finally, Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a report on Friday, March 29th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of GBX 6,497.06 ($84.90).

Shares of AZN stock opened at GBX 6,450 ($84.28) on Tuesday. AstraZeneca has a 1-year low of GBX 5,110 ($66.77) and a 1-year high of GBX 6,540 ($85.46). The company has a current ratio of 0.75, a quick ratio of 0.57 and a debt-to-equity ratio of 179.66. The firm has a market cap of $84.61 billion and a PE ratio of 33.95.

In related news, insider Marc Dunoyer purchased 8,500 shares of AstraZeneca stock in a transaction on Tuesday, May 7th. The stock was bought at an average price of GBX 5,800 ($75.79) per share, with a total value of £493,000 ($644,191.82). Also, insider Philip A. J. Broadley purchased 520 shares of AstraZeneca stock in a transaction on Tuesday, April 30th. The stock was bought at an average cost of GBX 5,738 ($74.98) per share, with a total value of £29,837.60 ($38,988.11).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: Average Daily Trade Volume – What It Means In Stock Trading

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Amcor plc  Given $10.74 Average Target Price by Brokerages
Amcor plc Given $10.74 Average Target Price by Brokerages
Zacks: EP Energy Corporation  Given $1.21 Consensus Target Price by Analysts
Zacks: EP Energy Corporation Given $1.21 Consensus Target Price by Analysts
Brokerages Expect Stoke Therapeutics  to Post  Earnings Per Share
Brokerages Expect Stoke Therapeutics to Post Earnings Per Share
Zacks: Analysts Expect CNH Industrial NV  to Post $0.29 Earnings Per Share
Zacks: Analysts Expect CNH Industrial NV to Post $0.29 Earnings Per Share
Exelixis, Inc.  Expected to Announce Earnings of $0.25 Per Share
Exelixis, Inc. Expected to Announce Earnings of $0.25 Per Share
Zacks: Analysts Anticipate Triplepoint Venture Growth BDC Corp  to Announce $0.38 Earnings Per Share
Zacks: Analysts Anticipate Triplepoint Venture Growth BDC Corp to Announce $0.38 Earnings Per Share


© 2006-2019 Ticker Report